United Republic of Tanzania
Tuberculosis profile
| High TB burden | High HIV burden |
Population  2013 49 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 6 (3.4–8.2) 12 (7–17)
Mortality (HIV+TB only) 6.1 (4.8–7.5) 12 (9.8–15)
Prevalence  (includes HIV+TB) 85 (45–140) 172 (92–277)
Incidence  (includes HIV+TB) 81 (77–84) 164 (157–170)
Incidence (HIV+TB only) 30 (29–31) 61 (58–63)
Case detection, all forms (%) 79 (77–83)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.1 (0.5–2) 3.1 (0.9–7.9)
MDR-TB cases among notified pulmonary
TB cases
530 (240–960) 86 (25–220)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 24 565   1 101
Pulmonary, clinically diagnosed 23 371    
Extrapulmonary 15 016    
       
Total new and relapse 64 053    
Previously treated, excluding relapses 1 679    
Total cases notified 65 732    
Among 62 952 new cases:
6 658 (11%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 192 (5%) 728 (26%) 2 020
Laboratory-confirmed RR-/MDR-TB cases     279
Patients started on MDR-TB treatment     93
TB/HIV 2013 Number (%)
TB patients with known HIV status 54 504 (83)
HIV-positive TB patients 20 320 (37)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 19 835 (98)
HIV-positive TB patients on antiretroviral therapy (ART) 14 864 (73)
HIV-positive people screened for TB 457 901  
HIV-positive people provided with IPT 166  
Treatment success rate (%)
New and relapse cases registered in 2012 90
Previously treated cases, excluding relapse, registered in 2012 80
HIV-positive TB cases, all types, registered in 2012 77
RR-/MDR-TB cases started on second-line treatment in 2011 75
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.9
Culture (per 5 million population) 0.5
Drug susceptibility testing (per 5 million population) 0.1
Sites performing Xpert MTB/RIF 35
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 61
% Funded domestically 13%
% Funded internationally 17%
% Unfunded 69%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-19 Data: www.who.int/tb/data